Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Inxmed (Nanjing) Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is situated in 1 distinct art unit. The company's current engagement with the patent office is limited to this 1 active case. This singular focus allows the company to maintain a very consistent argument and strategy while addressing the specific concerns of the patent office in this technical field.
MAHLUM, JONATHAN DAVIS is the busiest examiner for this portfolio, responsible for the 1 pending office action. Since there is only 1 distinct examiner and 1 distinct art unit, the prosecution landscape is very simple. The company's immediate success in the biotechnology sector is tied to the outcome of this 1 pending office action under the review of MAHLUM, JONATHAN DAVIS. Practitioners should focus on establishing a clear dialogue with this 1 examiner to move the case toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18627032 | DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18627032 | DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF | MAHLUM, JONATHAN DAVIS | 1625 | §102§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInxmed (Nanjing) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jonathan Davis Mahlum has the most, with 1 of Inxmed (Nanjing) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
